Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0VFEIE)
| ADC Name |
BR111
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
BR111; BR111A
Click to Show/Hide
|
|||||
| Organization |
Biorui Biotech (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Anti-ROR1 mAb
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
Eribulin
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Reactive Cysteines
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Unspecific non-hodgkin lymphoma |
1 Trials
|